RxDoctor Payments Data

Dheera Tamvada, MD

Internal Medicine · Modesto, CANPI 1225552284

Payments from drug & device makers

$501in general payments, 2019–2025

Across 29 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$184
  • Pfizer$57
  • Gilead$44
  • Jazz Pharmaceuticals Inc.$40
  • Shire North American Group Inc$38
  • Otsuka America Pharmaceutical, Inc.$24
  • plus $115 from 7 others

What the payments were for

  • Food & beverage$501100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$501 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$229
Medicare patients
14
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin31$42,996
TradjentaLinagliptin11$14,583
Spiriva RespimatTiotropium Bromide18$9,036
JanumetSitagliptin Phos/Metformin Hcl12$8,917
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$7,912
SymbicortBudesonide/Formoterol Fumarate15$3,641
Albuterol Sulfate HfaAlbuterol Sulfate68$2,402
Atorvastatin Calcium176$2,093
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic32$1,893
Gabapentin97$1,608
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,432
Levothyroxine Sodium73$988
Lisinopril93$895
Losartan Potassium95$864
Ultra-Fine Short Pen NeedlePen Needle, Diabetic13$719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$16$66,61560 claims
MerckJanumet$11$8,91712 claims
AstraZenecaSymbicort$184$3,64115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →